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Abstract
To analyze the association between change in HbA1c during the first 6 years after diagnosis
of Type 2 diabetes mellitus (Type 2 DM) and incident micro- and macrovascular morbidity
and mortality during 13 years thereafter. This is an observational study of the participants in
the intervention arm of the randomized controlled trial Diabetes Care in General Practice
(DCGP) in Denmark. 494 newly diagnosed persons with Type 2 DM aged 40 years and over
with three or more measurements of HbA1c during six years of intervention were included in
the analyses. Based on a regression line, fitted through the HbA1c-measurements from 1 to
6 years after diabetes diagnosis, glycaemic control was characterized by the one-year level
of HbA1c after diagnosis, and the slope of the regression line. Outcomes were incident dia-
betes-related morbidity and mortality from 6 to 19 years after diabetes diagnosis. The asso-
ciation between change in HbA1c (the slope of the regression line) and clinical outcomes
were assessed in adjusted Cox regression models. The median HbA1c level at year one
was 60 (IQR: 52–71) mmol/mol or (7.65 (IQR: 6.91–8.62) %). Higher HbA1c levels one year
after diagnosis were associated with a higher risk of later diabetes-related morbidity and
mortality. An increase in HbA1c during the first 6 years after diabetes diagnosis was associ-
ated with later microvascular complications (HR per 1.1 mmol/mol or 0.1% point increase in
HbA1c per year; 95% CI) = 1.14; 1.05–1.24). Change in HbA1c did not predict the aggregate
outcome ‘any diabetes-related endpoint, all-cause mortality, diabetes-related mortality,
myocardial infarction, stroke, or peripheral vascular diseases. We conclude that suboptimal
development of glycaemic control during the first 6 years after diabetes diagnosis was an
independent risk factor for microvascular complications during the succeeding 13-year fol-
low-up, but not for mortality or macrovascular complications.
Background
In general, persons with Type 2 diabetes mellitus (Type 2 DM) have an increased cardiovascu-
lar morbidity and mortality [1, 2], and an elevated haemoglobin A1c (HbA1c) increases the risk
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of both micro- and macrovascular complications in these persons [3–5]. Randomized con-
trolled trials have shown that treatment with anti-diabetic medication lowers the risk of com-
plications[6]. It is unknown if the lower risk associated with anti-diabetic treatment is fully
attributable to the lowering of HbA1c levels [7], or that other pleiomorphic factors, such as the
pharmaceutical properties of the anti-diabetic drugs, account for this effect.
The Diabetes Care in General Practice (DCGP) study was a cluster randomized controlled
trial assessing the effect on mortality and morbidity of structured personal care compared with
routine care in a population-based sample of persons newly diagnosed with clinical Type 2
DM in Denmark [8]. After six years, the structured personal care group had improved glycae-
mia, blood pressure, total cholesterol, and microalbuminuria. There were no differences in
terms of morbidity and mortality between the two groups [8]. However, a 19-year follow-up of
the DCGP study showed that participants in the intervention group had a lower incidence of
myocardial infarction and ‘any diabetes-related outcome’, while mortality rate was similar
between the two groups [9]. The intervention group displayed a large inter-individual varia-
tion in HbA1c [10]. On average, an initial drop in HbA1c was observed, followed by an increase
during the remaining five years of the intervention period. Only age and HbA1c at time of
diagnosis were predictive of the variation in HbA1c during follow-up [10].
Earlier studies have used a single HbA1c measurement [5] or an average of several HbA1c
measurements [11] to predict later outcomes. In the present confirmatory study, the aim was
to determine the relation between changes in HbA1c during 6 years of intervention in persons
with newly diagnosed Type 2 DM and any diabetes-related endpoint, all-cause mortality, dia-
betes-related mortality, myocardial infarction, stroke, peripheral vascular disease and micro-
vascular disease during the 13 years thereafter.
Participants and methods
Study design and population
This is a cohort study of the intervention group from the DCGP study, a cluster randomized
controlled trial. Informed consent was obtained from all participants. The protocol was in
accordance with the Helsinki declaration and was approved by the ethics committee of Copen-
hagen and Frederiksberg (V.100.869/87). All data were fully anonymized before they were
accessed. In 1988, 474 general practitioners volunteered to take part in the study. These were
randomized to structured personal care or routine care [8]. All doctors were to include all par-
ticipants aged 40 years or over with newly diagnosed diabetes (Fig 1). The treatment guidelines
in the intervention group included follow-up every three months and individualized goal set-
ting for each participant supported by prompting of doctors, printed guidelines, feedback, and
continuing medical education. The control group was not included in the present analysis, as
yearly HbA1c measurements were performed only in the intervention group. Hence, this study
is confined to the 536 participants who were alive and were examined at the end of the inter-
vention 6 years after the diabetes diagnosis. Participants with less than three HbA1c measure-
ments between 1 year after diagnosis and 6-year follow-up were excluded. The final study
sample included 494 participants (Fig 1). As only 2.5% of the cohort started insulin treatment
within 180 days after diagnosis, we consider that 97.5% had Type 2 DM [12].
Definition of glycaemic control (determinants)
At the time of diabetes diagnosis and at the annual examinations, the fraction of HbA1c was
determined by the same ion-exchange, high-performance liquid chromatography method
with a relatively high reference interval (5.4–7.4% (36–57 mmol/mol)) at Odense University
Hospital [8]. In general, participants experienced an improved glycemic control with a more
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or less pronounced remission of hyperglycaemia during the first year after diabetes diagnosis
[10, 13]. To determine the individual development in glycaemic control, we fitted linear
regression lines to the HbA1c measurements from one to (on average) six years after the diag-
nosis for each participant individually. Glycaemic control was then characterized for each
Fig 1. Flow chart depicting the number of participants in the Diabetes Care in General Practice (DCGP) study included in the
current study.
https://doi.org/10.1371/journal.pone.0225230.g001
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individual participant from this regression line, firstly, by the one-year intercept of the regres-
sion line (“one-year HbA1c level”) and, secondly, as the slope of the regression line (“yearly
HbA1c change”) [10] (see Fig 2).
Definition of outcomes
The outcomes were all-cause mortality, diabetes-related mortality (i.e. cardiovascular mortal-
ity, death due hypo- and hyperglycemia, and sudden death) myocardial infarction, stroke,
peripheral vascular disease, and microvascular disease, any diabetes-related endpoint (i.e. pres-
ence of any of the aforementioned categories) (please see S1 Table for the exact definitions of
the different outcomes). If a participant had an outcome at the time of diabetes diagnosis, the
participant was excluded from the analyses of that specific outcome. Outcomes were assessed
in the Danish registries until 31 December 2008. The vital and emigration status of all partici-
pants were ascertained through the Danish Civil Registration System [14]. Information on
morbidity and causes of death were retrieved from the National Hospital Discharge Registry
[15] and Danish Register of Causes of Death [8].
Covariates
Covariates were selected based on measured confounders known to affect both mortality and
HbA1c. Information about covariates was collected at 6-year follow-up [10]. Age, sex, and
cohabitation status (dichotomous: living alone yes/no) were registered. Body mass index
(BMI, kg/m2) was calculated based on height measured at the time of diagnosis and weight
measured at the end of the intervention, on average 6 years later, by the general practitioner
Fig 2. Graphic depiction of the covariate LEVEL at year one of the 6-year intervention period after diagnosis and the SLOPE of
the change in HbA1c from year 2 through 6 year of the intervention period.
https://doi.org/10.1371/journal.pone.0225230.g002
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with the scales available in the clinic. Wasting/pathological weight loss was defined as uninten-
tional weight loss� 1 kg per year (wasting yes/no) (16). Current smoking status was dichoto-
mized (yes/no). Information about leisure time physical activity (LTPA) was assessed from
the International Physical Activity Questionnaire and dichotomized as “sedentary LTPA yes/
no” [16]. Hypertension was defined as systolic blood pressure� 160, and/or diastolic
pressure� 90 mmHg, and/or antihypertensive and/or diuretic treatment. Laboratory tests
included total cholesterol (mmol/l), fasting triglycerides (mmol/l), serum creatinine (μmol/l),
and urinary albumin (mg/l). Type of treatment at the end of intervention was categorized as:
diet only, oral antidiabetic, or insulin.
Statistical methods
The effect of one-year HbA1c levels was expressed as hazard ratios (HRs) calculated using a
Cox proportional hazard regression model indicating the multiplicative change in incidence
rate (hazard) per 1.1 mmol/mol or (0.1% point) increment in HbA1c. The effect of the yearly
HbA1c change (the slope of the regression line) on the outcome was expressed as HRs per 1.1
mmol/mol or (0.1% point) increase in HbA1c/year. The effect of the 1-year HbA1c level and
yearly change in HbA1c was assessed in unadjusted as well as in adjusted models: Model 1
included age, sex, living alone, BMI (and one-year HbA1c levels in the analyses including
change); Model 2 additionally included hypertension, total cholesterol, triglycerides, LTPA,
smoking status, and wasting. To assess the linearity of the effect of glycaemic control, a
restricted cubic spline was used to model the effect of glycaemic control after adjustment as in
Model 2. Sensitivity analyses were performed adjusted for urinary albumin, creatinine, and
anti-diabetic medication (Model 3). To investigate if one-year HbA1c level, sex, and anti-dia-
betic medication affected the relation between the yearly HbA1c change and risk of morbidity
and mortality, we repeated the aforementioned analyses, stratified on one-year HbA1c level,
sex, and type of treatment. All analyses were performed in SAS (Version 9.4).
To validate the linearity assumptions of our general linear regression models, we performed
non-linear spline regression analyses on the associations between yearly HbA1c change and the
clinical outcomes. The incidence of microvascular disease increased approximately linearly
with increasing slope of the regression line (data not shown).
Results
The median age was 69.1 year at the end of the intervention, on average six years after diagno-
sis, and 50% of participants were men (Table 1). At the end of follow-up, 62% received oral
anti-diabetic medication and 29% was treated with diet only. One year after diagnosis, HbA1c
levels were on average lower than at time of diagnosis. During the following five years the
observed average HbA1c increased with 0.19% per year (95% confidence interval (95% CI):
0.01–0.43) (Table 1), (equivalent to a rise of. 2.1 mmol/mol (95% CI: 0.11–4.70)).
Higher HbA1c levels one year after diagnosis were associated with a higher risk of later dia-
betes-related morbidity and mortality (all p value < 0.05; see Table 2).
Next we assessed the relation between yearly HbA1c changes dichotomized on the median
(0.188 percentage point per year during the 6-year intervention period) and the incidence of
various outcomes during the 13 years thereafter. Table 3 shows the risk for various outcomes
for those with a median or higher increase in HbA1 levels during the intervention period, rela-
tive to those with change in HbA1c below the median. An increase in HbA1C levels equal or
higher than median was associated with a higher risk of myocardial infarction during the fol-
low-up.
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Table 4 shows the relation between continuous changes in HbA1c levels during the inter-
vention period Change in HbA1c during the intervention period was not associated with the
aggregate outcome any diabetes-related endpoint, all-cause mortality, diabetes-related mortal-
ity, myocardial infarction, and stroke in the multivariable analyses. However, yearly HbA1c
change was associated with a higher incidence of microvascular complications (HR, 95% CI:
1.14, 1.05–1.24) and peripheral vascular disease (1.14, 1.00–1.30). In sensitivity analyses, when
additionally adjusting for urinary albumin, creatinine, and anti-diabetic medication, the asso-
ciation between yearly HbA1c change and microvascular disease remained (1.11; 1.01–1.21;
P = 0.024), but the association with peripheral vascular disease was attenuated (1.05; 0.89–1.24;
P = 0.58).
Table 1. Participant characteristics.
n Characteristics
Baseline HbA1c level (mmol/mol)
1 411 88 (72–103)
Baseline HbA1c level (%)
1 10.2 (8.7–11.6)
One-year HbA1c level (mmol/mol)
1 494 60 (52–71)
One-year HbA1c level (%)
1 7.65 (6.91–8.62)
Yearly HbA1c change (mmol/mol/year) 494 2.1 (0.11–4.70)
Yearly HbA1c change (%/ year) 0.19 (0.01–0.43)
Age at end study (years) 494 69.1 (60.1–77.4)
Sex (male) (n,%) 494 244 (49.4)
Living alone (n,%) 459 167 (36.4)
BMI (kg/m2) 483 28.3 (25.6–31.7)
Baseline systolic blood pressure (mmHg) 489 150 (132–160)
Baseline diastolic blood pressure (mmHg) 489 85 (80–90)
Systolic blood pressure (mmHg) 492 149 (132–160)
Diastolic blood pressure (mmHg) 492 80 (80–90)
Hypertension 2 (n,%) 494 361 (73.1)
Total cholesterol (mmol/l) 491 6.0 (5.2–6.8)
Fasting triglycerides (mmol/l) 463 1.73 (1.22–2.50)
Sedentary leisure time physical activity 453 128 (28.3)
Smoking (n,%) 457 146 (32.0)
Wasting 3 (n,%) 494 82 (16.6)
Anti-diabetic treatment (n,%) 494
Diet only 142 (28.7)
Oral agents 304 (61.5)
Insulin 48 (9.7)
Serum creatinine (μmol/l) 491 89 (80–103)
Urinary albumin (n,%) 468
Normal 290 (62.0)
Microalbuminuria 158 (33.8)
Proteinuria 20 (4.3)
Unless otherwise stated, participant characteristics are from six years after diabetes diagnosis. Data are numbers (%)
or medians (interquartile range (IQR)). N denotes the number of participants for whom variables were available.
1Reference value 36–57 mmol/mol (5.4–7.4%);
2Hypertension: systolic/diastolic blood pressure� 160 and/or 90 mmHg;
3Wasting: unintentional weight loss� 1 kg per year in participants without intention to lose weight.
https://doi.org/10.1371/journal.pone.0225230.t001
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In additional analyses, we investigated whether the effect of yearly HbA1c change on the
outcomes was dependent on the participant’s characteristics, such as one-year HbA1c level,
sex, and type of anti-diabetic treatment (Table 5). The relation between yearly HbA1c change
and incidence of all-cause and diabetes-related mortality was stronger for women than for
Table 2. Relation between one-year level of haemoglobin A1c and risk of outcomes during 13 years of post-intervention follow-up.
Events before or during
intervention (n, %)
Events during post-
intervention follow-up
(n, %)
Model 1 Model 2 Model 3
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Any diabetes-related endpoint 157 (31.9) 196 (58.3) 1.24
(1.09–1.41)
0.001 1.26
(1.10–1.45)
0.001 1.19
(1.01–1.41)
0.03
All-cause mortality - 295 (59.7) 1.14
(1.02–1.27)
0.02 1.18
(1.05–1.33)
0.006 1.14
(0.98–1.33)
0.09
Diabetes-related mortality - 186 (37.8) 1.18
(1.02–1.35)
0.02 1.24
(1.07–1.44)
0.005 1.3
(1.08–1.55)
0.005
Myocardial infarction 46 (9.4) 121 (27.1) 1.16
(0.96–1.38)
0.09 1.22
(1.01–1.48)
0.04 1.34
(1.05–1.70)
0.02
Stroke 47 (9.5) 78 (17.5) 1.42
(1.12–1.79)
0.004 1.46
(1.13–1.88)
0.004 1.37
(0.98–1.91)
0.07
Peripheral vascular disease 2 (0.4) 20 (4.1) 2.05
(1.44–2.91)
<0.0001 1.85
(1.28–2.68)
0.001 1.43
(0.93–2.21)
0.10
Microvascular disease 15 (3.1) 54 (11.3) 1.55
(1.24–1.92)
0.0001 1.68
(1.33–2.13)
<0.0001 1.48
(1.12–1.96)
0.006
Events are given as count data with percentages (%). Other data are given as hazard ratios (HR) with 95% confidence interval (CI) and corresponding p values for
outcomes during 13 years of post-intervention follow-up expressed per 1.1 mmol/mol (0.1%) increment in levels of HbA1c at 1 year after diagnosis. Model 1 is adjusted
for age, sex, living alone, and BMI. Model 2: as model 1, but additionally adjusted for hypertension, cholesterol, triglycerides, sedentary leisure time physical activity,
smoking, and wasting. Model 3: as model 2, but additionally adjusted for anti-diabetic medication, urinary albumin, and creatinine.
https://doi.org/10.1371/journal.pone.0225230.t002
Table 3. Relation between dichotomized change in haemoglobin A1c during the 6-year intervention period and risk of outcomes during the subsequent 13 years of
follow-up.
Events before or during
intervention (n, %)
Events during post-
intervention follow-up
(n, %)
Model 1 Model 2 Model 3
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Any diabetes-related endpoint 157 (31.9) 196 (58.3) 0.91
(0.65–1.28)
0.59 0.92
(0.63–1.32)
0.63 0.82
(0.55–1.22)
0.33
All-cause mortality - 295 (59.7) 1.22
(0.94–1.60)
0.14 1.24
(0.94–1.64)
0.13 1.12
(0.83–1.50)
0.46
Diabetes-related mortality - 186 (37.8) 1.40
(0.99–1.98)
0.060 1.40
(0.96–2.03)
0.077 1.27
(0.86–1.86)
0.23
Myocardial infarction 46 (9.4) 121 (27.1) 1.81
(1.17–2.79)
0.0074 2.14
(1.30–3.52)
0.0030 2.07
(1.26–3.41)
0.0040
Stroke 47 (9.5) 78 (17.5) 0.95
(0.52–1.73)
0.86 1.01
(0.51–2.02)
0.98 0.89
(0.43–1.85)
0.76
Peripheral vascular disease 2 (0.4) 20 (4.1) 2.09
(0.70–6.19)
0.19 1.47
(0.55–3.95)
0.45 1.02
(0.40–2.63)
0.97
Microvascular disease 15 (3.1) 54 (11.3) 1.67
(0.85–3.27)
0.13 1.71
(0.85–3.47)
0.14 1.49
(0.74–3.05)
0.27
Events are given as count data with percentages (%). Other data are given as hazard ratios (HR) with 95% confidence interval (CI). Hazard ratios denote the effect of
HbA1c change equal and above median relative to HbA1c change below the median during the 6-year intervention period after diagnosis on outcomes during 13 years
of post-intervention. Model 1 is adjusted for age, sex, living alone, BMI, and one-year HbA1c level. Model 2: as model 1, but additionally adjusted for hypertension,
cholesterol, triglycerides, sedentary leisure time physical activity, smoking, and wasting. Model 3: as model 2, but additionally adjusted for anti-diabetic medication,
urinary albumin, and creatinine.
https://doi.org/10.1371/journal.pone.0225230.t003
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men (p for interaction 0.033 and 0.038 respectively). Regarding the modifying effect of diabetic
medication, treatment with insulin was associated with an increased risk of diabetes-related
mortality compared to participants treated with oral medication or diet only. Moreover, oral
medication was a risk indicator for later myocardial infarction when compared to diet only
and insulin therapy.
Discussion
In this Danish population-based sample of persons with newly diagnosed Type 2 DM, a higher
yearly increase in HbA1c was an independent risk factor for microvascular disease, but not for
macrovascular disease or mortality during the subsequent 13-years in participants receiving
structured personal care in general practice. The relation between yearly HbA1c change and
the incidence of microvascular outcomes appeared to be linear. Although increasing HbA1c
was associated with a higher incidence of peripheral vascular disease, this association was no
longer significant after correction for urinary albumin, creatinine, and anti-diabetic medica-
tion. These findings were independent of the level of HbA1c after one year of treatment. We
found no association between an increase in HbA1c during the intervention period and mor-
tality or incident cardiovascular events during 13 years of follow-up. In the DCGP trial the
intervention reduced the incidence of myocardial infarction after 19 years of follow-up com-
pared with the control group (9). This time point coincides with the end of the 13-year follow-
up in the present study. Thus, the present observational study suggest that the reduction in
macrovascular disease may not attributable to quality of HbA1c control during the intervention
period. but may bedue to other elements of the intervention like blood pressure control. Alter-
natively, the lower macrovascular morbidity in the DCGP study at 19 years may be the results
of the legacy effect, the long-term health benefits of early glycemic control.
Table 4. Relation between yearly change in haemoglobin A1c during the 6-year intervention period and risk of outcomes during the subsequent 13 years of follow-
up.
Events before or during
intervention (n, %)
Events during post-
intervention follow-up
(n, %)
Model 1 Model 2 Model 3
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Any diabetes-related endpoint 157 (31.9) 196 (58.3) 0.99
(0.95–1.04)
0.71 1
(0.95–1.05)
0.94 0.98
(0.92–1.03)
0.42
All-cause mortality - 295 (59.7) 1.01
(0.97–1.05)
0.66 1.02
(0.98–1.07)
0.32 1.00
(0.96–1.06)
0.82
Diabetes-related mortality - 186 (37.8) 1.00
(0.96–1.05)
0.86 1.01
(0.96–1.07)
0.63 1.00
(0.94–1.07)
0.96
Myocardial infarction 46 (9.4) 121 (27.1) 1.02
(0.96–1.08)
0.57 1.04
(0.97–1.11)
0.23 1.06
(0.99–1.14)
0.10
Stroke 47 (9.5) 78 (17.5) 1.02
(0.94–1.10)
0.65 1.04
(0.95–1.14)
0.40 1.01
(0.91–1.13)
0.81
Peripheral vascular disease 2 (0.4) 20 (4.1) 1.17
(1.05–1.30)
0.006 1.14
(1.00–1.30)
0.047 1.05
(0.89–1.24)
0.59
Microvascular disease 15 (3.1) 54 (11.3) 1.11
(1.03–1.20)
0.006 1.14
(1.05–1.24)
0.002 1.11
(1.01–1.21)
0.024
Events are given as count data with percentages (%). Other data are given as hazard ratios (HR) with 95% confidence interval (CI) and corresponding p values for
outcomes during 13 years of post-intervention follow-up expressed per 1.1 mmol/mol (0.1%) per year change in HbA1c during the 6-year intervention period after
diagnosis. Model 1 is adjusted for age, sex, living alone, BMI, and one-year HbA1c level. Model 2: as model 1, but additionally adjusted for hypertension, cholesterol,
triglycerides, sedentary leisure time physical activity, smoking, and wasting. Model 3: as model 2, but additionally adjusted for anti-diabetic medication, urinary
albumin, and creatinine.
https://doi.org/10.1371/journal.pone.0225230.t004
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Table 5. Modifying effect of one-year HbA1c level, sex, and antidiabetic treatment, on the relation between yearly change in in haemoglobin A1c during the 6-year
intervention period and risk for various outcomes during the subsequent 13-year post-intervention follow-up.
Effect
modifier
Events before or during intervention
(n, %)
Events during post-intervention follow-
up (n, %)
HR (95% CI) P value P for
interaction
HbA1c level, mmol/mol (%)
Any diabetes-related
endpoint
�57.4
(7.4)
59 (28.5) 74 (50.0) 0.95 (0.87–
1.04)
0.24 0.14
>57.4
(7.4)
98 (34.3) 122 (64.9) 1.01 (0.96–
1.06)
0.77
All-cause mortality �57.4
(7.4)
0 118 (57.0) 1.04 (0.98–
1.11)
0.22 0.49
>57.4
(7.4)
0 177 (61.7) 1.01 (0.97–
1.06)
0.58
Diabetes-related mortality �57.4
(7.4)
0 72 (34.8) 1.01 (0.93–
1.10)
0.78 0.97
>57.4
(7.4)
0 114 (40.0) 1.01 (0.95–
1.08)
0.66
Myocardial infarction �57.4
(7.4)
18 (8.7) 49 (25.2) 1.07 (0.97–
1.18)
0.15 0.46
>57.4
(7.4)
29 (9.8) 72 (28.0) 1.03 (0.95–
1.11)
0.45
Stroke �57.4
(7.4)
17 (8.2) 23 (12.1) 0.93 (0.77–
1.13)
0.47 0.16
>57.4
(7.4)
30 (10.5) 55 (21.5) 1.05 (0.96–
1.15)
0.25
Peripheral vascular disease �57.4
(7.4)
1 (0.5) 4 (1.9) 1.14 (0.92–
1.41)
0.24 0.99
>57.4
(7.4)
1(0.4) 16 (5.6) 1.14 (1.00–
1.30)
0.048
Microvascular disease �57.4
(7.4)
5 (2.4) 15 (7.4) 1.10 (0.95–
1.27)
0.21 0.49
>57.4
(7.4)
10 (3.5) 39 (14.2) 1.15 (1.06–
1.25)
0.001
Sex
Any diabetes related
endpoint
Women 78 (31.3) 103 (60.2) 1.02 (0.96–
1.09)
0.47 0.18
Men 79 (32.4) 93 (56.4) 0.98 (0.92–
1.03)
0.41
All-cause mortality Women 0 133 (53.2) 1.07 (1.01–
1.13)
0.017 0.033
Men 0 162 (66.4) 0.99 (0.94–
1.04)
0.67
Diabetes related mortality Women 0 86 (34.5) 1.07 (1.00–
1.15)
0.049 0.038
Men 0 100 (41.2) 0.97 (0.91–
1.04)
0.46
Myocardial infarction Women 19 (7.6) 55 (23.9) 1.09 (1.01–
1.18)
0.027 0.15
Men 27 (11.1) 66 (30.9) 1.01 (0.92–
1.10)
0.89
Stroke Women 22 (8.8) 35 (15.4) 1.08 (0.96–
1.21)
0.20 0.35
Men 25 (10.3) 43 (19.6) 1.02 (0.92–
1.13)
0.72
Peripheral vascular disease Women 1 (0.4) 5 (2.0) 1.01 (0.74–
1.37)
0.95 0.32
(Continued)
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Table 5. (Continued)
Effect
modifier
Events before or during intervention
(n, %)
Events during post-intervention follow-
up (n, %)
HR (95% CI) P value P for
interaction
Men 1 (0.4) 15 (6.2) 1.17 (1.03–
1.33)
0.012
Microvascular disease Women 6 (2.4) 26 (10.7) 1.15 (1.03–
1.28)
0.010 0.78
Men 9 (3.7) 28 (12.0) 1.13 (1.02–
1.25)
0.017
Antidiabetic treatment
Any diabetes-related
endpoint
Diet only 42 (29.6) 50 (50.0) 0.91 (0.84–
1.00)
0.046 0.030
Oral 99 (32.7) 124 (60.8) 1.02 (0.96–
1.09)
0.43
Insulin 16 (33.3) 22 (68.8) 0.93 (0.83–
1.04)
0.22
All-cause mortality Diet only 0 84 (59.2) 0.93 (0.86–
1.01)
0.074 0.021
Oral 0 181 (59.5) 1.04 (0.99–
1.10)
0.11
Insulin 0 30 (62.5) 1.04 (0.96–
1.12)
0.33
Diabetes-related mortality Diet only 0 60 (42.3) 0.95 (0.86–
1.04)
0.26 0.023
Oral 0 105 (34.8) 1.04 (0.97–
1.11)
0.29
Insulin 0 21 (43.8) 1.11 (1.01–
1.22)
0.030
Myocardial infarction Diet only 14 (9.9) 36 (28.1) 0.95 (0.86–
1.06)
0.36 0.036
Oral 28 (9.3) 74 (27.0) 1.10 (1.02–
1.19)
0.019
Insulin 4 (8.3) 11 (25.0) 1.05 (0.93–
1.19)
0.46
Stroke Diet only 19 (13.4) 19 (15.5) 0.97 (0.84–
1.13)
0.71 0.57
Oral 23 (7.6) 47 (16.8) 1.05 (0.94–
1.17)
0.37
Insulin 5 (10.4) 12 (27.9) 1.04 (0.89–
1.21)
0.66
Peripheral vascular disease Diet only 0 (0.0) 1 (0.7) 1.48 (1.17–
1.86)
0.001 0.053
Oral 2 (0.7) 14 (4.7) 1.07 (0.90–
1.28)
0.45
Insulin 0 (0.0) 5 (10.4) 1.12 (0.90–
1.39)
0.30
Microvascular disease Diet only 4 (2.8) 6 (4.4) 1.03 (0.90–
1.19)
0.67 0.29
Oral 10 (3.3) 41 (14.0) 1.15 (1.05–
1.26)
0.002
Insulin 1 (2.1) 7 (14.9) 1.06 (0.83–
1.36)
0.64
Events are given as count data (n) with percentages (%). Other data are given as hazard ratios (HR) with 95% confidence interval (CI) and corresponding p values for
outcomes during 13 year post-intervention follow-up expressed per 1.1 mmol/mol (0.1%) per year change in HbA1c during 6-year intervention period after diagnosis
adjusted for age, sex, living alone, BMI, hypertension, total cholesterols, triglycerides, leisure time physical activity, smoking, and wasting.
https://doi.org/10.1371/journal.pone.0225230.t005
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A recent study investigated the relation between the difference in HbA1c levels before and
after 6 months of treatment with metformin and the subsequent risk of cardiovascular events
and mortality. This study found that a decrease in HbA1c during 6 months of treatment was
associated with a lower risk of cardiovascular events and mortality during a median follow-up
of 2.8 years in participants [17]. Admittedly, the statistical precision of these results was limited
and, since all participants used metformin, it is possible that the effect was due to the pharma-
cological properties of metformin instead of the decrease in HbA1c. Yet in line with these ear-
lier findings, we also found that increasing HbA1c levels during the six-year intervention
period were associated with an increased risk of microvascular complications and a tendency
towards higher risk of peripheral vascular morbidity. Increasing levels of HbA1c during the
intervention period may have been caused by a less intensive treatment of diabetes, or may be
ascribed to diabetes subtype, weight gain, or other factors. A meta-analysis demonstrated that
intensive treatment of Type 2 DM lowers the risk of microvascular complications as well as the
risk of amputation of lower extremities. [18]. However, this meta-analysis failed to show an
effect on macro-vascular morbidity. A follow-up study of the Veteran Affair Diabetes Trial
(VADT) concluded that intensive treatment may reduce the risk of major cardiovascular
events, but that the intervention did not lower mortality risk [19]. Thus, overall taken, results
regarding the risk of increasing HbA1c levels are not consistent between studies. This may in
part be due to methodological heterogeneity, e.g. differences in treatment regimens, duration
of follow-up, and definition of quality of glycaemic control as well as participant characteristics
and compliance issues.
The UKPDS study is comparable to the DCGP study, in that it included persons with newly
diagnosed Type 2 DM, while the ADVANCE and ACCORD studies included persons already
diagnosed with diabetes with comorbid cardiovascular disease and a mean diabetes duration
of eight and ten years, respectively [20, 21]. In UKPDS, the measure of HbA1c was an updated
mean of HbA1c based on the mean of the annual measurements during follow-up, which
mathematically is essentially the same analysis we conducted for the current study. The
UKPDS found that a 1% lower updated mean HbA1c was associated with a 37% lower risk for
microvascular complications, and a 43% lower risk of the combined endpoint of amputation
or death by peripheral vascular disease [11]. These results by and large concord with our find-
ings. However, unlike the UKPDS study, which reported a lower all-cause and diabetes-related
mortality of respectively 14% and 21% per 1% lower updated mean HbA1c [11, 21], we only
found an association between HbA1c and mortality in women. A sex-specific difference in dia-
betes outcomes is reminiscent of earlier findings in the DCGP study of a post-hoc analysis
between structured personal care compared with routine care [12]. Women receiving struc-
tured personal care showed a lower all-cause mortality, incidence of diabetes-related mortality,
and any diabetes-related endpoint than women receiving routine care, while this difference
was absent in men. This sex-related difference was ascribed to complex social and cultural
issues involving gender [12]. Regarding microvascular complications, the UKPDS concluded
that the rate of increase of the risk for microvascular disease with hyperglycaemia was larger
than that for macrovascular disease [11].
A major strength of this study is the prospective design and the long-term post-trial follow
up. Use of Danish registry data ensured that follow-up was virtually complete [10]. The
included sample is likely to be representative of community-dwelling persons with Type 2 DM
that have survived for some years with this diagnosis and have followed a structured disease
management program, which nowadays is included in the clinical guidelines for diabetes. The
change in HbA1c over time is a highly clinically relevant parameter since decisions on treat-
ment adjustments are typically based on HbA1c measurements. The inclusion of repeated
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HbA1c measurements is anticipated to take into account a considerable proportion of the vari-
ation in the disease progression in persons with Type 2 DM [15].
Microvascular disease was treated as a surrogate measure of disease status. The outcome is
a composite outcome including renal complications and eye-related complications, and the
effect sizes in our study were expectedly attenuated when results were adjusted for urinary
albumin and antidiabetic treatment.
Our study has a number of shortcomings. The analyses in this study are based on informa-
tion of the disease progression during the intervention of the trial, and no information was
available on treatment or HbA1c levels during the succeeding 13 years of follow-up. However,
it has been shown that although glucose regulation deteriorates in treatment groups after the
end of the intervention, a beneficial “legacy effect” on cardiovascular end-points may persist
[22] [23]. A second shortcoming is large number of significance tests performed. We had no
predefined ideas on how changes in HbA1c would affect later diabetes-related outcomes. The
study is therefore hypothesis generating, and the found associations should therefore be con-
firmed in subsequent, hypothesis confirming studies. This implicates though that the typical
p-value threshold of 5% should be interpreted with caution.
Conclusions
In conclusion, increasing HbA1c levels during the first six years after the diagnosis of Type 2
DM were associated with a higher incidence of microvascular complications, but not macro-
vascular complications and mortality during the following 13 years. These findings should fur-
ther encourage clinicians to pursue optimal glycaemic control to prevent long-term
microvascular complications in persons with Type 2 DM.
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